Introduction
Globally, Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting around 1% of people aged 60 years and older. 1 PD was first described by James Parkinson in 1817, who reported on symptoms including tremor, poor posture and muscle loss in six individuals. 2 Traditionally the motor symptoms of PD, including rigidity, tremors and bradykinesia, were thought of as the cardinal features of the disease. PD is more commonly considered a syndrome that encompasses other symptoms such as cognitive loss, sleep disturbances, loss of the ability to smell and gastrointestinal problems. PD is characterised by the loss of dopaminergic neurons of the substantia nigra (SN) pars compacta (SNpc), noradrenergic neurons in the locus coeruleus and the accumulation of insoluble protein inclusions known as Lewy bodies throughout the basal ganglia, which eventually Paul A. Adlard Paul Adlard's research focuses on promoting healthy brain ageing. By gaining an understanding of the mechanisms that lead to age-related dysfunction we can subsequently apply this knowledge to provide a targeted and novel therapeutic strategy to maintain/improve brain health. The current focus of the lab is understanding the role that metals play in the cellular events and pathways that occur during both normal and pathological ageing (particularly Alzheimer's disease) that are related to synaptic plasticity and cognitive function.
including those affected by PD. Elevated Fe levels in the SN has thus become an important target in PD research. 10 Hyperechogenicity of the SN, measurable through ultrasonography, has been associated with increased nigral Fe and microglial activation in PD. 11 Preliminary studies of a large cross-sectional group of subjects found that 8 otherwise healthy adults displaying hyperechogenicity had developed clinical PD symptoms in follow-up consultations, suggesting hyperechogenicity, and therefore elevated nigral Fe levels were present prior to physical manifestation of the clinical defined disease. 12 Thus, it is becoming more widely accepted that deriving the association between metal dyshomeostasis and PD progression is an important step in understanding both the cause of disease and developing therapeutics. Significant attention is being paid to examining metallobiology in both human PD and the various Parkinsonian animal models used to study disease aetiology. A successful Parkinsonian model must thus mimic the metal dyshomeostasis of idiopathic PD in addition to other typical pathological features in order to provide a complete model of disease. This review will focus upon metal metabolism in one of the primary research tools utilised for PD research: the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxin model.
Metals and MPTP toxicity: cause or effect?
J. William Langston's pioneering work in the 1980s 13 paved the way for the widespread use of MPTP as an in vivo neurotoxin that recapitulates some aspects of the neuronal loss observed in PD. The acute neurotoxicity was first described in detail after a number of drug users developed L-3,4-dihydroxyphenylalanine-(L-DOPA) responsive PD symptoms after administering the synthetic opioid 1-methyl-4-phenyl-4-propionoxypiperidine contaminated with 3% MPTP, which was confirmed by post mortem identification of lesions in the SN. 14 The subsequent symptoms, disease progression and pathology of these people was indistinguishable from the sporadic form of the disease and as such has initiated its use in research. 15 Jackson-Lewis and Przedborski 16 identified this, along with the relative ease of administration compared to other candidates and the consistent lesion as the major reasons MPTP is commonly chosen for PD research. The MPTP model still engenders controversy regarding the applicability of the results to the human condition, mainly as the toxin does not illicit all the symptoms or the progressive nature of the human disease. potent complex I inhibitor, interfering with the first step of the electron transport chain, decreasing cellular ATP production, inhibiting mitochondrial enzymes and increasing the synthesis of reactive oxygen species (ROS). [19] [20] [21] Importantly, complex I inhibition is a feature of MPP + toxicity mirrored in idiopathic PD. 22, 23 MPP + also stimulates increased ROS formation in the cytoplasm, independent of mitochondrial inhibition, 24 suggesting the mechanism of cell death is multifaceted. Cell damage resulting from ROS is promoted by the presence of redox-active metals, such as Fe, which mediate the formation of harmful hydrogen peroxide and hydroxyl radicals via Fenton chemistry. 25 Changes in metal levels and metabolism following MPTP-induced neurotoxicity are an important hallmark of the toxin that appears to mirror metal dyshomeostasis in humans, and taken together suggest the role of metals in dopaminergic cell death. The role of metals in MPTP-induced neuron loss was first discussed by Poirier et al., 26 who found that MPTP and high concentrations of transition metals potentiate autoxidation of dopamine (DA) through increased production of reactive oxygen species (ROS). The fact that DA-rich neurons are more susceptible to cell death in both PD and MPTP-treated cells suggests that DA catabolism plays a major role. Autoxidation of DA occurs through two pathways: (i) MAO on the surface of mitochondria coverts DA to an aldehyde intermediate that is further metabolised to 3,4-dihydroxyphenylacetic acid, or DOPAC; and (ii) oxidation of the catechol moiety forms an electron-deficient DA quinone. 27 The redox-active properties of transition metals including Fe, Cu and Zn may potentiate the oxidation of DA and formation of toxic species associated with this degradation pathway. Furthermore, the MPTP-induced elevation of such metals could contribute to the rapid neuron death cascade observed following insult, accelerating the DA-mediated cell loss observed in idiopathic PD.
Redox active metals such as Mn have been shown to cause nigral cell death in a manner mimicking the action of neurotoxins like MPP + . 28 Further, Mn inhibits the activity of tyrosine hydroxylase, the enzyme responsible for the conversion of L-tyrosine to L-DOPA thus decreasing striatal DA. Mn could also stimulate reduction of striatal DA concentrations directly through DA autoxidation. However, more recent studies 29 directly comparing Mn administration with MPTP insult suggests Mn alone does not produce comparable neurotoxicity, and that there is no potentiating effect of Mn when administered 3 weeks prior to MPTP administration. Mn exposure did increase astrocyte activity in the globus pallidus of treated C57BL/6 mice. Paradoxically, Mn administration for 7 days prior to MPTP insult demonstrated a capacity to increase DA by up to 60% compared to MPTP treatment alone. 30 The conflicting data described here regarding the role of Mn in mitigating and/or accentuating MPTP toxicity highlights a significant limitation in generalising the effects of all redox active metals and the role they play in the toxin's mode of action.
Redox active metals are implicated in ROS generation and ultimately cell death; therefore, pre-treatment of subjects with metals can significantly alter homeostasis before MPTP insult occurs, potentially complicating interpretation of MPTP as a model for cell death in PD. In their protocol for producing the MPTP mouse model of PD, Jackson-Lewis and Przedborski 16 concentrations in 24 idiopathic PD patients compared to a 34-strong control group, possibly explaining reduced ferroxidase activity from Cu-binding ceruloplasmin observed in a later study of PD cases. 40 Imaging of Cu distribution in MPTP lesioned mice brains found decreased Cu in periventricular regions up to 7 days after administration, which either returned to or exceeded pre-dosing levels 28 days following. 41 However, the role of Cu in PD pathogenesis may be independent of the cell death observed following MPTP intoxication; Cu has been shown to play a role in the aggregation of insoluble a-synuclein-based Lewy bodies, 42 a feature observed in human PD that is not mirrored in MPTP models. 43, 44 If Cu-mediated Lewy body formation is indeed one of the major pathways through which altered Cu metabolism contributes to neuron loss in PD, interpretation of data describing changes in Cu levels following MPTP should take this into account. As with all metals, the various roles of Cu in numerous cellular processes do somewhat limit decisive conclusions that can be drawn from experimental data when comparing human disease states to animal models.
Does iron metabolism following MPTP insult reflect changes in PD?
Iron has been implicated more than any other redox active metal in PD pathogenesis. Since Lhermitte's early observations of 1924, 4 significant attention has been given to elucidating the role of Fe in neuron death. Typical features of generalised Fe overload in the cell closely mirror those observed in PD, including increased ROS production, decreased activity of antioxidant proteins and inhibition of mitochondrial enzymes, including complex I. 45 Importantly, numerous biochemical characteristics of Fe overload are also present following MPTP administration.
A proposed mechanism of Fe-mediated MPTP neurotoxicity is presented in Fig. 1 . In vitro studies of MPTP in astrocyte cultures found that glial conversion to MPP + by MAO activity is the primary method of bioactivation, but redox-active Fe also contributes to the formation of the toxic metabolite. 46 MPP + is released into the cytosol and taken up into neurons via the dopamine transporter (DAT), where it accumulates and stimulates cellular dysfunction and death by mitochondrial failure (by way of inhibition of mitochondrial complex I) and increased oxidative stress (the theorised pathway involving Fe). 47 Thus, the role of Fe in MPTP-induced cell loss appears to be multidimensional: Fe is not only involved in the production of cytotoxic species through metal-mediated O 2 À production, but also in the generation of the toxic moiety MPP + from its parent MPTP molecule. Further evidence for the role of Fe in MPTP toxicity has been uncovered at the genetic level. Gene expression profiling of MPP + -exposed MN9D dopaminergic cells found 51 genes that exhibited a significant response to the toxin compared to control, with known functions including apoptosis, cellular metabolism, signal transduction and oxidative stress. Using Gene Ontology for Function Analysis (GOFFA), a functional tree of gene expression related to Fe binding was deduced. All six of the identified genes were down regulated, four of which were associated with oxidative stress (Cdo1, P4ha1, Rrm2, Tbxas1), 48 62 Paraquat, a cation that displays similar structural properties to MPP + , promotes complete release of Fe from ferritin, though electron spin resonance spectroscopy showed paraquat did not induce structural deformities in ferritin chains and that the protein regained the ability to reincorporate Fe into its structure. 63 Ferritin levels in PD have not demonstrated a clear increase in expression, rather changes observed in idiopathic PD are somewhat ambiguous. 64 Nigral ferritin immunoreactivity has been described as decreasing (with a corresponding increase in total Fe, suggesting Fe storage capacity may be compromised) 6 and increasing (with corresponding increase in Fe 3+ , suggesting ferritin expression may be in response to elevated Fe) 65, 66 in PD.
The significance of ferritin in Fe metabolism is clear, and the role it plays in cell death mechanisms found in both MPTP toxicity and idiopathic PD is undoubtedly of great importance in elucidating PD pathogenesis. However, it is uncertain if ferritin's role in PD progression is contributory to cell death or reactionary, as part of the cell's defence mechanism.
Interaction between ferritin and MPTP may still hold key information regarding the risk factors of elevated Fe in the aging brain. MRI analysis of ferritin in the human brain in vivo suggested ferritin levels increase in the caudate, putamen, globus pallidus, thalamus and hippocampus (but decreased in the frontal lobes) with age. 67 Ferritin accumulation in the SN of human PD brains appears confined to glia. 68 One theory supporting age-related changes in ferritin-accumulating cells and associated Fe toxicity is the ability of ferritin to release Fe 2+ in response to elevated O 2 À levels. 69 Hence, accumulation of ferritin with age could indeed provide a viable source of Fe for the increasing labile Fe pool, entering neurons via microglial activation and uptake through divalent metal transporter-1 (DMT1) on the neuronal membrane. A lack of ferritin up-regulation in SN neurons of human PD cases may explain the increases in available brain Fe and heightened susceptibility to neuron loss with age. 70 Disruption of ferritin expression or activity in the neuron may limit the cell's practical defences against sudden Fe influx, increasing the labile Fe pool and causing oxidative damage. Thus, alterations in ferritin levels occurring with age have a direct effect on nigral Fe and susceptibility to Fe-related oxidative stress that occurs in the aging brain. MPTP has been employed to study the possible influence of this progressive change in brain Fe. Histochemical study of Fe deposits in two age groups of macaque monkeys given a single unilateral MPTP injection found that dense, focal deposits of Fe were only observed in the SN of older (>7 years) monkey and no significant variation in MPTP-induced neuron loss was obvious between the two groups. The Fe deposits were observed bilaterally, with the authors suggesting this was indicative of Fe deposition prior to lesioning 71 Variation in tau protein and Fe concentrations were also observed in MPTP lesioned mice. Tau is a microtubule-associated protein that is linked to a variety of neurodegenerative disorders, termed tauopathies. Modifications to tau, such as phosphorylation and glycosylation are thought to play a major role in tau mediated neuronal toxicity. 79 A possible mechanism demonstrating tau involvement in Fe trafficking has been proposed, where tau contributes to amyloid precursor protein (APP) surface activity. APP has ferroxidase activity, 80 where it interacts with membrane ferroportin to shunt Fe from the cell. Loss of tau in primary cell cultures resulted in marked Fe accumulation. Similarly, in MPTP treated mice a decrease in tau levels was observed in the SN three days after acute dosage, remaining suppressed until day forty-five post treatment, with a corresponding increase in nigral Fe. 81 In human PD, oxidation of ceruloplasmin, a
Cu-binding ferroxidase protein, has shown a similar effect of reducing cellular Fe export leading to increased Fe retention. 82 Fe is transported into neurons through either delivery by transferrin (Tf) to membrane receptors or via DMT1.
83 DMT1
facilitates the rapid transfer of Fe from the extracellular spaces into the cytoplasm, as either free Fe 2+ or by mediation of a ferric reductase enzyme. 84 Decreased ferroportin, in addition to increased levels of DMT1 have been observed in the SN dopaminergic neurons of MPTP-treated mice, with corresponding Fe accumulation, though not in similar neurons of the adjacent ventral tegmental area (VTA). 85 Increased expression of DMT1
has also been reported in the SNpc of human PD samples, in line with an observed elevation in DMT1 expression in MPTP intoxicated mice. 86 It is still unclear as to why DA neurons in the VTA of mice are resistant to MPTP challenge yet adjacent neurons in the SNpc are vulnerable, though recent evidence suggested that VTA neurons demonstrate a functional genetic response to MPTP insult including ion/metal regulatory genes (PANK2 and Car4) that is not observed in SNpc DA neurons. 87 Increased Fe in at-risk areas of the brain has been extensively described in both idiopathic PD and MPTP models. Indeed, Fe accumulation is a common theme in various neurological disorders with parkinsonian pathology, as reviewed by Berg and Hochstrasser, 88 as well as generalised inflammation in PD. 89 While it is apparent that elevated Fe contributes to MPTP-mediated neuron loss, the precise mechanism by which Fe stimulates oxidative damage is still not clear; in fact it is probable that perturbations to Fe regulatory systems within the cell contribute to the formation of toxic species through multiple pathways. Commonality between Fe accumulation and oxidative stress would suggest Fe involvement in neuron loss is not necessarily a causative factor in PD; however altered iron metabolism has shown promise as a target for novel therapeutics, justifying targeting cellular Fe handling as an import field of study. Regardless, most reports have described Fe-related factors in isolation, due mostly to the difficulties in observing Fe metabolism as a whole. Improving techniques will ensure that Fe and MPTP toxicity, and thus PD pathogenesis will remain a keenly investigated topic for some time.
MPTP stimulates a cellular metallomic response
Changes to redox-active metal levels in the PD brain may not directly contribute to elevated levels of oxidative stress; metals such as Cu and Zn are also key functional components of antioxidant proteins (see Fig. 2 ). The changes in metal levels observed in MPTP are most likely intertwined: altered Fe levels induce increased oxidative stress, leading to an influx of metalbinding proteins (such as superoxide dismutases -SOD) that scavenge the evolved free radicals, mitigating cell damage. Major proteins with antioxidant properties include Cu, Zn-and Mn-SOD and Cu/Zn binding metallothioneins (MTs). Cellular Zn homeostasis has been implicated as a factor that may be involved in neurodegenerative processes and diseases, with Zn ionophores showing efficacy in restoring cognition in animal models of Alzheimer's disease. 90, 91 Increasing concentrations of Zn 2+ with age may contribute to increased mitochondrial ROS formation. 92 It is thus not surprising that Zn has exhibited dyshomeostasis in MPTP models of PD. Mice exposed to acute doses of MPTP possessed degenerating neurons in the SNpc that showed an accumulation of cytosolic Zn compared to saline-treated controls, 93 though increased brain Zn may be more generally indicative of brain trauma. 94 Mice administered moderate amounts of Zn did not display depleted DA levels, though co-administration of Zn with MPTP significantly lowered DA, suggesting a possible potentiating effect of Zn on MPTP toxicity. 95 Zn may, however, be indicative of a cellular response to MPTP injury involving endogenous antioxidant proteins like Cu,Zn-SOD. 90% of brain Zn is protein-bound, the remaining 10% of labile Zn is confined to presynaptic vesicles. 96 Rojas et al. 97 reported that, following MPP + insult, the number of Zn-positive terminals decreased in the mouse striatum and increased in the stratum radiatum and stratum oriens regions of the CA2 zones of the hippocampus. This efflux of Zn could be indicative of a rapid mobilisation of ionic Zn preceding synthesis of MT 98 and Cu,Zn-SOD, both antioxidant proteins known to scavenge free radicals. 99 displayed increased activity in the SN region. 103 Increased nigral Mn-SOD activity was confirmed in additional studies, along with an observed decrease in SN Cu,Zn-SOD activity following MPTP lesioning. Pretreatment of mice with 17b-estradiol, a sex hormone, increased Cu,Zn-SOD and Mn-SOD immunoreactive neurons postinsult, though not reactive glia. 104 Both Cu,Zn-SOD and Mn-SOD null mice display heightened sensitivity to MPTP lesioning, whereas mutation to both SOD1 (Cu,Zn) and SOD2 (Mn) genes demonstrate resistance to the toxin compared to control. 20 In human PD, an increase in Mn-SOD mRNA was observed in line with decreased Cu,Zn-SOD expression in the SN, 105 agreeing with decreased Cu,Zn-SOD and increased Mn-SOD immunoreactivity in the SN of MPTP treated mice. 106 MPTP lesioning of common marmosets demonstrated loss of Cu,Zn-SOD mRNA throughout the basal ganglia, most marked in the SNpc. This loss of a major antioxidant enzyme (in conjunction with depletion of glutathione peroxidase in both the SNpc and SNr) has also been observed in human PD patients, 108 further supporting the hypothesis that metal dyshomeostasis in MPTP-mediated cell death is indeed reflective of PD etiology. Little information is available directly comparing Cu,Zn-SOD activity and total Cu and Zn levels in either MPTP models or human PD. Analysis of blood taken from PD patients found red cell Cu,Zn-SOD activity was increased, as was red cell Cu and Zn, in addition to plasma Cu levels compared to control donors. 109 It is difficult, however, to infer the significance of altered circulating Cu,Zn-SOD activity compared to expression in the brain. Correlating Cu,Zn-SOD and total metal levels is challenging, considering that these metals are also active components of other metalbinding proteins. Cu,Zn-SOD is a very active Cu and Zn binder, and any loss of capacity to uptake free Cu and Zn may increase intracellular metal levels and thus redox activity. 110 However, the role of other proteins with affinity to Cu and Zn increasing uptake of metals in direct response to decreased Cu,Zn-SOD has not been studied and is deserving of attention.
Metallothioneins are a group of 0.5-14 kDa proteins containing approximately 25-30% cysteine residues 111 that have shown potential protective features in a range of genetic PD animal models. 112 The large sulfur-component of MTs results in a strong affinity to group 11 and 12 metals, including endogenous Cu and Zn and heavy metals such as cadmium (Cd) and mercury (Hg). These cysteine residues are also capable of chaperoning ROS, removing the threat of cellular damage through reduction of the harmful species. Like SOD, MTs are thought to play a role in mitigating oxidative damage through attenuation of ONOO À synthesis. 113 While metal ions do not play a direct role in ROS or RNS removal by MTs, the mere presence of elevated metal concentration can induce MT expression. In SK-N-SH cell lines grown in Zn-rich media increased MT expression help prevent cell death from methamphetamine toxicity. 114, 115 Induction of MT expression by exposure to Cd and dexamethasone (a known MT induction factor) five hours prior to MPTP insult resulted in increased DA levels compared to non-induced animals. 116 However, there is some contention regarding the role of MT isoforms following MPTP neurotoxicity. Rojas and Klaassen 117 reported that the DA denervation by MPTP was not attenuated in MT knock-out mice. MT expression was, however, observed to decrease in the striatum of mice in response to a MPP + challenge; 118 this observation was supported by data demonstrating a reduction in MT-1 mRNA. 119, 120 Unfortunately, relatively little information is present in literature describing changes in MT levels in the PD brain. Further study into how MTs are expressed and distributed in the human dopaminergic pathway is required. In addition to its role in promoting oxidative stress through changes to the labile Fe pool, other metalloenzymes also rely upon Fe for activity. TH uses O 2 , tetrahydrobiopterin and Fe as cofactors in its role in DA synthesis. Loss of TH activity precludes DA conversion from L-DOPA, accounting for marked DA decrease following MPTP administration. Monkeys given an MPTP insult displayed decreased TH mRNA compared to unlesioned animals. 121 In human PD, surviving dopaminergic neurons have shown similar decreases in TH mRNA levels. neuroblastoma SHSY-5Y cells. 123 Active metal chaperones like the orally bioavailable and blood-brain barrier-permeable 5-chloro-7-iodo-8-hydroxyquinoline (clioquinol) and associated 8-hydroxyquinoline analogues have shown potential as therapeautics for several neurodegenerative disorders, 124 even so far as to demonstrate applicability in restoring cognition in animal models of Alzheimer's disease 90 and improving executive function in human clinical trials. 125 In clioquinol-treated animals given acute MPTP doses, increases in markers of oxidative stress and corresponding decreases in cellular antioxidants normally seen following MPTP leisoning were not observed. 127 The MAO inhibitory properties of 8-hydroxyquinoline compounds stem from the N-propargyl group common to clinical anti-Parkinson's drugs rasagiline and selegiline. 128 Selegiline has shown significant effectiveness in both protecting against MPTP toxicity (as does rasagiline) 129 and slowing PD progression in human trials. 130 While MAO inhibition may prevent both MPTP to MPP + conversion in animal models, as well as limiting DA autoxidation in human PD, interaction with metal metabolism may be present. Selegiline has been suggested to both promote SOD expression, and limit Fe-mediated DA oxidation in several models of PD, including MPTP, 131 which may reflect a partial mode of action for the compound in humans independent of MAO inhibition. R-Apomorphine is a MAO inhibitor and dopamine D 1 -D 2 receptor agonist that has demonstrated similar effectiveness to L-DOPA as a treatment for PD in humans. 132 In addition to its affinity to dopamine receptors, R-apomorphine is also an effective free radical scavenger and Fe-chelator that, when concurrently administered to mice with MPTP, showed possible neuroprotective features suggestive of antioxidant properties, as opposed to impeding MPP + formation through MAO inhibition. 133 Ginsenoside Rg1, an active component of ginseng root has shown potential beneficial properties in pretreated mice exposed to MPTP. Rg1 treated animals displayed lower Fe-positive cell densities following MPTP administration, with decreased DMT1 and increased ferroportin expression, indicative of a shift towards pre-toxin Fe trafficking mechanisms. 134 Similar effects were observed in Rg1 pre-treated MES23.5 cells exposed to MPP + . 135 The Fe 3+ chelator deferrioxamine (also known as desferal and desferrioxamine) has shown conflicting data regarding its role in either potentiating or preventing MPTP toxicity. In MPP + treated rats, deferrioxamine was shown to enhance the formation of hydroxyl radicals in the striatum. 136 Conversely, pretreatment of SK-N-SH dopaminergic neurons in culture with deferrioxamine and coenzyme Q10 (an antioxidant enzyme) was shown to reduce the impact of Fe loading. Administration of diethyldithiocarbamate, a Cu chelator, to mice treated with MPTP resulted in potentiation of MPTP neurotoxicity with corresponding DA depletion and increased astrocyte activity at the site of lesion. 137 Cu-chelation does not necessarily result in MPTP potentiation; D-penicillamine (used to chaperone Cu in Wilson's disease) did not increase striatal DA depletion as diethyldithiocarbamate did; instead it showed some, albeit modest, prevention of MPTP-induced dopamine loss. 138 For further information, a range of Cu complexing agents was recently review by Duncan and White. 37 Chaperoning of metals via chelating or ionophoric compounds has shown great potential as viable therapeutics for treating neurodegenerative diseases, which is reflected by the range of compounds studied within the context of MPTPinduced neuron loss (Table 1) . Thus, the importance of properly elucidating the role of metals in PD and the suitability of MPTP as a model for metal-based neurodegeneration is integral to the development of next generation chelators and ionophores.
Metals and alternative parkinsonian toxins
Widespread use of MPTP to model PD is due not only to its clinically indistinguishable recapitulation of parkinsonism in humans and non human primates, but also its comparatively simpler method of administration compared to other neurotoxins. 16 However, distinct differences in the mode of toxicity of MPTP and alternative nigral insults cannot be disregarded when discussing the appropriateness of MPTP as a model for PD, particularly in relation to relating disease progression to metal metabolism. 6-Hydroxydopamine (6-OHDA) is a catecholamine with selective toxicity shown towards both DA and noradrenergic neurons. 139 Administration of 6-OHDA is somewhat more complicated; requiring stereotaxic injection of 6-OHDA into the nigra itself, medial forebrain bundle or caudate-putamen to produce the desired lesion of the nigrostriatal pathway.
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A major advantage of 6-OHDA over MPTP is the reported ability of the toxin to produce limited effects on the contralateral side, and a controllable loss of dopamine in the ipsilateral hemisphere. 141, 142 Controlled administration of 6-OHDA to only the nigrostriatal pathway, whilst leaving the mesolimbic pathway unaffected produces a lesion that is reflective of the pattern of cell loss observed in idiopathic PD. 143 Bilateral elevation in nigral Fe following unilateral 6-OHDA administration has been observed, though significant retention of Fe at the site of injection was also still observed 21 days postlesion. 144 Three-dimensional reconstruction of Fe distribution surrounding the SN using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) imaging found that this artefact arising from the lesioning procedure did not contribute to nigral Fe levels, 145 though most common analytical techniques for measuring metals lack the spatial specificity to resolve these sources of Fe. Ultrasound analysis of Fe in the SN of lesioned rats has also shown an increase Fe levels. 146 Significant unilateral reduction in striatal Fe and Cu and increase in periventricular Cu, measured by LA-ICP-MS, has also been reported 42 days after 6-OHDA administration. 147 The effect of 6-OHDA on metal metabolism in the nigrostriatal pathway does mirror MPTP in some key features. In cell culture down-regulation of ferroportin following 6-OHDA insult 159 which is an important feature of idiopathic PD not reflected in the MPTP paradigm. Paraquat does not directly interact with the mitochondrial electron transport chain, instead it partakes in redox cycling to produce the same increase in oxidative stress. 160 Relatively sparse information is available regarding the role of metals in rotenone and paraquat toxicity and how it relates to PD. Ceruloplasmin-null mice exposed to a low dose of rotenone over 28 days showed a significant effect on motor behaviour, pathology and oxidative stress markers compared to wild types, 161 suggestive again of antioxidant properties of the Cu ferroxidase protein. Rotenone also increases H-ferritin mRNA and protein synthesis in NIH3T3 fibroblasts and SH-SY5Y neuroblastoma cells. 162 Direct comparison of paraquat and MPP + toxicity in cell culture found that both molecules have a similar deleterious impact on cellular mRNA and protein expression related to intracellular iron transport. Paraquat toxicity is sometimes coupled with administration of complex III inhibitor maneb (manganese ethylene-bis-dithiocarbamate) to produce a modest, yet consistent lesion of the nigrostriatal pathway with minimal damage to surrounding regions. 163 Lactacystin is a relatively new alternative to MPTP for modelling PD in animals, stemming from concern regarding the failure of MPTP to reproduce all pathological features of PD. Lactacystin is a potent proteosomal inhibitor that, when injected directly into the SN reduces striatal DA and induces motor dysfunction in rats, as well as replicating Lewy-body formation in the cytoplasm by impairing the ubiquitin proteasome system (UPS), 164, 165 though it lacks the consistency of the lesion produced by MPTP. Iron regulatory gene profiling of cells exposed to lactacystin found evidence that the toxin promotes TfR expression, but not DMT-1 and mitochondrial Fe regulatory proteins as with MPP + . 166 Lactacystin-exposed MES23.5 cells also demonstrated H-unit ferritin and increased labile Fe, 167 mirroring the effects of protracted MPTP exposure.
Genetic overexpression of H-unit ferritin was shown to reduce lactacystin-mediated DA depletion and neuron loss. 168 As is the case with MPTP, several Fe chelators have shown some degree of protection and rescue in animals exposed to lacatcystin, including the 8-hydroxquinilone M30 169 and desferrioxamine, 170 suggesting Fe is also integral in the mode of action of lacatacystin. Chronic co-administration of MPTP and probenecid (MPTP/P; 4-(dipropylsulfamoyl)benzoic acid) is often used to enhance nigrostriatal damage by inhibiting the urinary and neuronal excretion of toxic MPTP metabolites. 171, 172 MPTP/P retains the hallmarks of traditional MPTP lesioning, whilst also producing proteinaceous inclusions with a-synuclein and ubiquitin immunoreactivity in both the SN and cortex. 173 This emerging model presents an intriguing possibility to study the metallobiology of PD in a system exhibiting both Fe elevation and metal-protein aggregation. Copper was recently shown to play a role in ubiquitin aggregation in vitro. 174 Whilst ubiquitin accumulation is not unique to Parkinson's disease, 175 this toxin model provides a more complete picture of both PD pathology, as well as metal-mediated neurodegeneration.
Conclusion
MPTP remains the most commonly used model for preclinical testing of new therapies for PD, as well as playing an important role in investigating the mechanisms of dopaminergic neuron loss. 16 Most research into MPTP metallobiology tends to examine factors in isolation, rather than investigating the effect of altered metal homeostasis on the multitude of intersecting pathways that are relevant to the pathogenesis of PD. As such, there are several examples where interpretation of changes in metal content following MPTP administration may not be truly indicative of the toxin's mode of action, and thus not representative of idiopathic PD. This does not, however, discredit the use of MPTP as a viable PD model for studying metal-mediated cellular response. Significant evidence points to an apparent dual mechanism of toxicity for MPTP, through both complex I inhibition and increasing the labile Fe pool in the cell. These changes in harmful Fe levels appear to mirror the alterations in Fe observed in human PD cases, as do the changes in expression of important metal-binding enzymes, including Cu,Zn-SOD and Mn-SOD. Several therapeutic agents that have shown potential in treating PD have a mechanism of action that is also attributed to an affinity for redox-active metals, which has been shown in MPTP models of disease.
A major barrier to building a comprehensive picture of metallobiology in PD stems from the ubiquity of the very metals implicated in the disease, in that their varied roles and functions are difficult to study in toto. Viewing each metal-mediated process in isolation cannot account for the knock-on effects of altered metal homeostasis. Further development of more holistic systems biology approaches to studying metal metabolism will help better understand not only MPTP as a model for PD, but cell metallobiology as a whole.
